KR100699285B1 - 인터페론-베타와 같은 분비 단백질을 암호화하는 유전자를이용한 치료 방법 및 조성물 - Google Patents

인터페론-베타와 같은 분비 단백질을 암호화하는 유전자를이용한 치료 방법 및 조성물 Download PDF

Info

Publication number
KR100699285B1
KR100699285B1 KR1020007002157A KR20007002157A KR100699285B1 KR 100699285 B1 KR100699285 B1 KR 100699285B1 KR 1020007002157 A KR1020007002157 A KR 1020007002157A KR 20007002157 A KR20007002157 A KR 20007002157A KR 100699285 B1 KR100699285 B1 KR 100699285B1
Authority
KR
South Korea
Prior art keywords
interferon
cells
vector
gene
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007002157A
Other languages
English (en)
Korean (ko)
Other versions
KR20010023511A (ko
Inventor
제임스 지 바섬
알버트 크시아오 퀸
Original Assignee
바이오겐 아이덱 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 아이덱 엠에이 인코포레이티드 filed Critical 바이오겐 아이덱 엠에이 인코포레이티드
Publication of KR20010023511A publication Critical patent/KR20010023511A/ko
Application granted granted Critical
Publication of KR100699285B1 publication Critical patent/KR100699285B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020007002157A 1997-08-29 1998-08-25 인터페론-베타와 같은 분비 단백질을 암호화하는 유전자를이용한 치료 방법 및 조성물 Expired - Fee Related KR100699285B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
US60/057,254 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (2)

Publication Number Publication Date
KR20010023511A KR20010023511A (ko) 2001-03-26
KR100699285B1 true KR100699285B1 (ko) 2007-03-26

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007002157A Expired - Fee Related KR100699285B1 (ko) 1997-08-29 1998-08-25 인터페론-베타와 같은 분비 단백질을 암호화하는 유전자를이용한 치료 방법 및 조성물

Country Status (24)

Country Link
EP (1) EP1007717B8 (enExample)
JP (3) JP4124565B2 (enExample)
KR (1) KR100699285B1 (enExample)
CN (1) CN100342019C (enExample)
AT (1) ATE316145T1 (enExample)
AU (1) AU740428B2 (enExample)
BR (1) BR9812138A (enExample)
CA (1) CA2300480C (enExample)
CY (1) CY1105029T1 (enExample)
CZ (2) CZ297314B6 (enExample)
DE (1) DE69833264T2 (enExample)
DK (1) DK1007717T3 (enExample)
EA (1) EA003256B1 (enExample)
EE (1) EE04873B1 (enExample)
ES (1) ES2257817T3 (enExample)
HU (1) HU224422B1 (enExample)
IL (2) IL134593A0 (enExample)
IS (1) IS2318B (enExample)
NO (1) NO20000990L (enExample)
NZ (1) NZ503401A (enExample)
PT (1) PT1007717E (enExample)
SK (1) SK286821B6 (enExample)
TR (1) TR200000532T2 (enExample)
WO (1) WO1999010516A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363676B1 (en) * 2001-01-22 2007-03-28 Biogen Idec MA Inc. Method of enhancing delivery of a therapeutic nucleic acid
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
CN114630670B (zh) * 2019-06-01 2025-03-11 西韦克生物技术有限责任公司 用于将基因编辑系统递送至真核细胞的细菌平台

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US6204052B1 (en) * 1994-08-16 2001-03-20 Introgene B.V. Adenoviral vectors with reduced TNF response and partial E3 region deletion
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Gene Therapy, Vol.3(1):31-38 (1996. 02) *
Human Gene Therapy, Vol.5(10):1217-1229 (1994.10) *

Also Published As

Publication number Publication date
TR200000532T2 (tr) 2000-11-21
AU740428B2 (en) 2001-11-01
HK1029599A1 (en) 2001-04-06
IS2318B (is) 2007-11-15
NZ503401A (en) 2003-01-31
HUP0002913A3 (en) 2003-08-28
CN100342019C (zh) 2007-10-10
EP1007717B1 (en) 2006-01-18
IL134593A0 (en) 2001-04-30
IL134593A (en) 2007-06-17
JP2005225888A (ja) 2005-08-25
NO20000990D0 (no) 2000-02-28
CA2300480C (en) 2010-01-05
CA2300480A1 (en) 1999-03-04
BR9812138A (pt) 2000-07-18
JP4219335B2 (ja) 2009-02-04
DE69833264D1 (de) 2006-04-06
WO1999010516A2 (en) 1999-03-04
EE04873B1 (et) 2007-08-15
DE69833264T2 (de) 2006-09-28
ATE316145T1 (de) 2006-02-15
PT1007717E (pt) 2006-06-30
IS5374A (is) 2000-02-11
CN1271391A (zh) 2000-10-25
EA003256B1 (ru) 2003-02-27
SK286821B6 (sk) 2009-06-05
KR20010023511A (ko) 2001-03-26
AU9205198A (en) 1999-03-16
HU224422B1 (hu) 2005-08-29
JP2004155786A (ja) 2004-06-03
CY1105029T1 (el) 2010-03-03
WO1999010516A3 (en) 1999-05-06
EE200000102A (et) 2000-12-15
CZ2000733A3 (cs) 2000-06-14
EP1007717A2 (en) 2000-06-14
JP4124565B2 (ja) 2008-07-23
HUP0002913A2 (hu) 2000-12-28
JP2001514010A (ja) 2001-09-11
JP3953458B2 (ja) 2007-08-08
EA200000270A1 (ru) 2000-10-30
ES2257817T3 (es) 2006-08-01
EP1007717B8 (en) 2006-05-03
CZ299095B6 (cs) 2008-04-23
NO20000990L (no) 2000-05-02
CZ297314B6 (cs) 2006-11-15
DK1007717T3 (da) 2006-05-29
SK2482000A3 (en) 2000-08-14

Similar Documents

Publication Publication Date Title
US6210939B1 (en) Recombinant adenoviral vector and methods of use
PL186073B1 (pl) Preparat farmaceutyczny, zwłaszcza do terapii genowej
KR100699285B1 (ko) 인터페론-베타와 같은 분비 단백질을 암호화하는 유전자를이용한 치료 방법 및 조성물
US6696423B1 (en) Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
CA2252470A1 (en) Treatment of human cancers with an adenovirus vector containing an interferon consensus gene
US20040266006A1 (en) Adenoviral vectors having a protein IX deletion
US20090175825A1 (en) Interferon alpha and antisense k-ras rna combination gene therapy
US20030091534A1 (en) Adenoviral vectors having a protein IX deletion
EP1679375A1 (en) Methods and compositions for cancer therapies using genes encoding interferon-beta
KR100389526B1 (ko) 재조합아데노바이러스벡터및사용방법
HK1029599B (en) Methods and compositions for cancer therapies using genes encoding interferon-beta
MXPA00002101A (es) Metodos y composiciones para terapias que utilizan genes que codifican proteinas secretadas como beta-interferon
HK1095356A (en) Methods and compositions for cancer therapies using genes encoding interferon-beta
US20030223962A1 (en) Delivery of gene products to the lung parenchyma via gene transfer to the pleura
US20020137212A1 (en) Adenoviral vectors having a protein IX deletion

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20110309

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120320

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120320

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000